Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions
Andersson, Tommy , Baxter, Blaise, Brouwer, Patrick A. , Brinjikji, Waleed , Costalat, Vincent , Dávalos, Antoni , Demchuk, Andrew M. , Dippel, Diederik W.J. , Fischer, Urs , Gilvarry, Michael , Gounis, Matthew J. , Gralla, Jan , Jansen, Olav , Kallmes, David F. , Khatri, Pooja , López‐Cancio, Elena , Majoie, Charles B.L.M. , Marquering, Henk A. , Narata, Ana Paula , Siddiqui, Adnan H. , Szikora, István , Vale, David, Hacke, Werner , Liebeskind, David S. , Kallmes, David, De Meyer, Simon F , Bendszus, Martin , Campbell, Bruce , Fiehler, Jens , Jovin, Tudor G. , Lees, Kennedy R. , Nogueira, Raul G. , Ringleb, Peter Arthur , Kummer, Rüdiger von , Yoo, Albert J. , Liebeskind, David S. , Siddiqui, Adnan H , Szikora, Istvan , Andersson, Tommy , Demchuk, Andrew M , Brouwer, Patrick , Fischer, Urs , Marquering, Henk A , Majoie, Charles B L M , Khatri, Pooja

Mayo Clinic

International Journal of Stroke | May 23, 2017 | Volume: 12 | Issue: 6 | Pages: 606-614

10.1177/1747493017709671 | PMID 28534706 Get It

Limited data exist on clot composition and detailed characteristics of arterial thrombi associated with large vessel occlusion in acute ischemic stroke. Advances in endovascular thrombectomy and related imaging modalities have created a unique opportunity to analyze thrombi removed from cerebral arteries. Insights into thrombus composition, etiology, physical properties and neurovascular interactions may lead to future advancements in acute ischemic stroke treatment and improved clinical outcomes. Advances in imaging techniques may enhance clot characterization and inform therapeutic decision-making prior to treatment and reveal stroke etiology to guide secondary prevention. Current imaging techniques can provide some information about thrombi, but there remains much to evaluate about relationships that may exist among thrombus composition, occlusion characteristics and treatment outcomes. Improved pathophysiological characterization of clot types, their properties and how these properties change over time, together with clinical correlates from ongoing studies, may facilitate revascularization with thrombolysis and thrombectomy. Interdisciplinary approaches covering clinical, engineering and scientific aspects of thrombus research will be key to advancing the understanding of thrombi and improving acute ischemic stroke therapy. This consensus statement integrates recent research on clots and thrombi retrieved from cerebral arteries and provides a rationale for further analyses, including current opportunities and limitations.
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia
Papaioannou, Dimitrios , Shen, Changxian , McNeil, Betina, Bill, Marius , Karunasiri, Malith, Burke, Matthew H. , Özer, Hatice Gülçin , Yilmaz, Selen, Zitzer, Nina C. , Behbehani, Gregory K. , Oakes, Christopher C. , Steiner, Damian J., Marcucci, Guido , Powell, Bayard L., Kolitz, Jonathan E. , Carter, Thomas H. , Wang, Eunice S. , Mrózek, Krzysztof , Bloomfield, Clara D. , Garzon, Ramiro , Dorrance, Adrienne M. , Nicolet, Deedra , Wang, Eunice S. , Croce, Carlo Maria , Caligiuri, Michael A.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 22, 2017 | Volume: 114 | Issue: 23 | Pages: No page available

10.1073/pnas.1703142114 | PMID 28533390 Get It

Significance In this work we report on the previously uncharacterized clinical and biological role for EGFL7 in acute myeloid leukemia (AML). Patients with increased EGFL7 mRNA expression had lower complete remission rates and shorter overall and event-free survival, demonstrating the clinical relevance of EGFL7 expression in cytogenetically normal AML. Our results show that AML blasts are able to synthesize and secrete EGFL7 protein, promoting autocrine blast cell growth. Inhibition of EGFL7 results in decreased proliferation and induces apoptosis of AML cells. Taken together, our data provide the rationale for targeting EGFL7 using blocking antibodies as a therapy for patients with AML.
Association of Long-term Opioid Therapy With Functional Status, Adverse Outcomes, and Mortality Among Patients With Polyneuropathy
Hoffman, E. Matthew , Watson, James C. , Sauver, Jennifer L. St. , Staff, Nathan P. , Klein, Christopher J. , St Sauver, Jennifer, Staff, Nathan P , Klein, Christopher J , St Sauver, Jennifer L

Mayo Clinic

JAMA Neurology | May 22, 2017 | Volume: 74 | Issue: 7 | Pages: 773

10.1001/jamaneurol.2017.0486 | PMID 28531306 Get It

Long-term risk of recurrence and regrowth after gross-total and subtotal resection of sporadic vestibular schwannoma
Jacob, Jeffrey T. , Carlson, Matthew L. , Tanaka, Shota , Tanaka, Minoru , Saito, Nobuhito , Lohse, Christine M. , Driscoll, Colin L. W., Link, Michael J. , Nakatomi, Hirofumi

Mayo Clinic

Journal of Neurosurgery | May 19, 2017 | Volume: 133 | Issue: 4 | Pages: 1052-1058

10.3171/2016.11.jns16498 | PMID 28524795 Get It

OBJECTIVEThe management of vestibular schwannoma (VS) remains controversial. One commonly cited advantage of microsurgery over other treatment modalities is that tumor removal provides the greatest chance of long-term cure. However, there are very few publications with long-term follow-up to support this assertion. The purpose of the current study is to report the very long-term risk of recurrence among a large historical cohort of patients who underwent microsurgical resection.METHODSThe authors retrospectively reviewed the medical records of patients who had undergone primary microsurgical resection of unilateral VS via a retrosigmoid approach performed by a single neurosurgeon-neurotologist team between January 1980 and December 1999. Complete tumor removal was designated gross-total resection (GTR), and anything less than complete removal was designated subtotal resection (STR). The primary end point was radiological recurrence-free survival. Time-to-event analyses were performed to identify factors associated with recurrence.RESULTSFour hundred fourteen patients met the study inclusion criteria and were analyzed. Overall, 67 patients experienced recurrence at a median of 6.9 years following resection (IQR 3.9–12.1, range 1.2–22.5 years). Estimated recurrence-free survival rates at 5, 10, 15, and 20 years following resection were 93% (95% CI 91–96, 248 patients still at risk), 78% (72–85, 88), 68% (60–77, 47), and 51% (41–64, 22), respectively. The strongest predictor of recurrence was extent of resection, with patients who underwent STR having a nearly 11-fold greater risk of recurrence than the patients treated with GTR (HR 10.55, p < 0.001). Among the 18 patients treated with STR, 15 experienced recurrence at a median of 2.7 years following resection (IQR 1.9–8.9, range 1.2–18.7). Estimated recurrence-free survival rates at 5, 10, 15, and 20 years following GTR were 96% (95% CI 93–98, 241 patients still at risk), 82% (77–89, 86), 73% (65–81, 46), and 56% (45–70, 22), respectively. Estimated recurrence-free survival rates at 5, 10, and 15 years following STR were 47% (95% CI 28–78, 7 patients still at risk), 17% (5–55, 2), and 8% (1–52, 1), respectively.CONCLUSIONSLong-term surveillance is required following microsurgical resection of VS even after GTR. Subtotal resection alone should not be considered a definitive long-term cure. These data emphasize the importance of long-term follow-up when reporting tumor control outcomes for VS.
Modular Fluted Tapered Stems in Aseptic Revision Total Hip Arthroplasty
Cottino, Umberto , Hanssen, Arlen D. , Lewallen, David G. , Berry, Daniel J. , Abdel, Matthew P. , Larson, Dirk R. , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | May 17, 2017 | Volume: 99 | Issue: 10 | Pages: 873-881

10.2106/jbjs.16.00423 | PMID 28509828 Get It

Background: Modular fluted tapered stems have become the most commonly employed category of femoral component in revision hip arthroplasty in North America as a result of favorable early results and simplicity of use. Despite wide adoption, the majority of published data are limited to relatively small series with modest follow-up. The goal of the current study was to determine the success rate and factors associated with success, failure, and complications of the use of modular fluted tapered stems in aseptic revision total hip arthroplasties (THAs) in a large patient cohort. Methods: We identified 519 aseptic femoral revisions during which a modular fluted tapered stem was utilized. Clinical outcomes, Kaplan-Meier survivorship, radiographic outcomes, and complications were assessed. The mean age at revision arthroplasty was 70 years, the mean body mass index (BMI) was 29 kg/m 2 , and the mean duration of follow-up was 4.5 years (range, 2 to 14 years). Results: The mean Harris hip score (HHS) improved significantly from 51 points preoperatively to 76 points at 2 years (p < 0.001). This improvement was maintained at the last follow-up evaluation (mean HHS = 75 points). At the time of the most recent follow-up, 16 femoral revisions had been performed: 6 because of aseptic loosening, 4 because of infection, 3 because of instability, 2 because of periprosthetic fracture, and 1 because of stem fracture. The 10-year survivorship was 96% with revision for any reason as the end point and 90% with any reoperation as the end point. Of the patients who were alive and had not undergone revision at the time of final follow-up, 12 had stem subsidence but all but 1 of these stems had stabilized after subsiding. Postoperative complications were noted in 12% of the cases. Repeat revision due to femoral component loosening was not correlated with the preoperative bone-loss category or patient demographic factors. Conclusions: In this large series, femoral revision with a modular fluted tapered stem provided a high rate of osseointegration and sustained improvement in clinical scores at the time of the last follow-up. There was also a high rate of successful implant fixation across all categories of preoperative bone loss and an acceptable rate of complications. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
An analysis from the Quality Outcomes Database, Part 2. Predictive model for return to work after elective surgery for lumbar degenerative disease
Asher, Anthony L. , Devin, Clinton J. , Archer, Kristin R. , Chotai, Silky , Bydon, Mohamad , Nian, Hui , Speroff, Theodore, Dittus, Robert S., Philips, Sharon, Shaffrey, Christopher I. , Foley, Kevin T. , McGirt, Matthew J., Park, Paul , Harrell, Frank E.

Mayo Clinic

Journal of Neurosurgery: Spine | May 12, 2017 | Volume: 27 | Issue: 4 | Pages: 370-381

10.3171/2016.8.spine16527 | PMID 28498069 Get It

OBJECTIVECurrent costs associated with spine care are unsustainable. Productivity loss and time away from work for patients who were once gainfully employed contributes greatly to the financial burden experienced by individuals and, more broadly, society. Therefore, it is vital to identify the factors associated with return to work (RTW) after lumbar spine surgery. In this analysis, the authors used data from a national prospective outcomes registry to create a predictive model of patients’ ability to RTW after undergoing lumbar spine surgery for degenerative spine disease.METHODSData from 4694 patients who underwent elective spine surgery for degenerative lumbar disease, who had been employed preoperatively, and who had completed a 3-month follow-up evaluation, were entered into a prospective, multicenter registry. Patient-reported outcomes—Oswestry Disability Index (ODI), numeric rating scale (NRS) for back pain (BP) and leg pain (LP), and EQ-5D scores—were recorded at baseline and at 3 months postoperatively. The time to RTW was defined as the period between operation and date of returning to work. A multivariable Cox proportional hazards regression model, including an array of preoperative factors, was fitted for RTW. The model performance was measured using the concordance index (c-index).RESULTSEighty-two percent of patients (n = 3855) returned to work within 3 months postoperatively. The risk-adjusted predictors of a lower likelihood of RTW were being preoperatively employed but not working at the time of presentation, manual labor as an occupation, worker’s compensation, liability insurance for disability, higher preoperative ODI score, higher preoperative NRS-BP score, and demographic factors such as female sex, African American race, history of diabetes, and higher American Society of Anesthesiologists score. The likelihood of a RTW within 3 months was higher in patients with higher education level than in those with less than high school–level education. The c-index of the model’s performance was 0.71.CONCLUSIONSThis study presents a novel predictive model for the probability of returning to work after lumbar spine surgery. Spine care providers can use this model to educate patients and encourage them in shared decision-making regarding the RTW outcome. This evidence-based decision support will result in better communication between patients and clinicians and improve postoperative recovery expectations, which will ultimately increase the likelihood of a positive RTW trajectory.
An analysis from the Quality Outcomes Database, Part 1. Disability, quality of life, and pain outcomes following lumbar spine surgery: predicting likely individual patient outcomes for shared decision-making
McGirt, Matthew J., Bydon, Mohamad , Archer, Kristin R. , Devin, Clinton J. , Chotai, Silky , Nian, Hui , Speroff, Theodore, Dittus, Robert S., Philips, Sharon, Shaffrey, Christopher I. , Foley, Kevin T. , Asher, Anthony L. , Park, Paul , Harrell, Frank E.

Mayo Clinic

Journal of Neurosurgery: Spine | May 12, 2017 | Volume: 27 | Issue: 4 | Pages: 357-369

10.3171/2016.11.spine16526 | PMID 28498074 Get It

OBJECTIVEQuality and outcomes registry platforms lie at the center of many emerging evidence-driven reform models. Specifically, clinical registry data are progressively informing health care decision-making. In this analysis, the authors used data from a national prospective outcomes registry (the Quality Outcomes Database) to develop a predictive model for 12-month postoperative pain, disability, and quality of life (QOL) in patients undergoing elective lumbar spine surgery.METHODSIncluded in this analysis were 7618 patients who had completed 12 months of follow-up. The authors prospectively assessed baseline and 12-month patient-reported outcomes (PROs) via telephone interviews. The PROs assessed were those ascertained using the Oswestry Disability Index (ODI), EQ-5D, and numeric rating scale (NRS) for back pain (BP) and leg pain (LP). Variables analyzed for the predictive model included age, gender, body mass index, race, education level, history of prior surgery, smoking status, comorbid conditions, American Society of Anesthesiologists (ASA) score, symptom duration, indication for surgery, number of levels surgically treated, history of fusion surgery, surgical approach, receipt of workers’ compensation, liability insurance, insurance status, and ambulatory ability. To create a predictive model, each 12-month PRO was treated as an ordinal dependent variable and a separate proportional-odds ordinal logistic regression model was fitted for each PRO.RESULTSThere was a significant improvement in all PROs (p < 0.0001) at 12 months following lumbar spine surgery. The most important predictors of overall disability, QOL, and pain outcomes following lumbar spine surgery were employment status, baseline NRS-BP scores, psychological distress, baseline ODI scores, level of education, workers’ compensation status, symptom duration, race, baseline NRS-LP scores, ASA score, age, predominant symptom, smoking status, and insurance status. The prediction discrimination of the 4 separate novel predictive models was good, with a c-index of 0.69 for ODI, 0.69 for EQ-5D, 0.67 for NRS-BP, and 0.64 for NRS-LP (i.e., good concordance between predicted outcomes and observed outcomes).CONCLUSIONSThis study found that preoperative patient-specific factors derived from a prospective national outcomes registry significantly influence PRO measures of treatment effectiveness at 12 months after lumbar surgery. Novel predictive models constructed with these data hold the potential to improve surgical effectiveness and the overall value of spine surgery by optimizing patient selection and identifying important modifiable factors before a surgery even takes place. Furthermore, these models can advance patient-focused care when used as shared decision-making tools during preoperative patient counseling.
Paget's Disease of the Temporal Bone: A Single-Institution Contemporary Review of 27 Patients
Deep, Nicholas L. , Besch‐Stokes, Jake , Lane, John I. , Driscoll, Colin L. W., Carlson, Matthew L. , Besch-Stokes, J G

Mayo Clinic

Otology & Neurotology | May 12, 2017 | Volume: 38 | Issue: 6 | Pages: 907-915

10.1097/mao.0000000000001430 | PMID 28498272 Get It

Objectives: To report a contemporary review from a single-institution series on Paget's disease of the temporal bone (PDTB). Study Design: Retrospective chart review of patients evaluated from 1998 to 2016. Setting: Quaternary referral center. Patients: Patients with radiographically confirmed PDTB. Main Outcome Measures: Clinical, audiological, and radiological features and management strategies of PDTB. Results: A total of 50 temporal bones in 27 patients (15 men) were diagnosed with PDTB. Symptoms at presentation included hearing loss (n = 23, 85%), headache (n = 18, 67%), dizziness (n = 14, 52%), tinnitus (n = 5, 19%), chronic otitis media (n = 2, 7%), hemifacial spasm without facial paralysis (n = 1, 4%), multiple cranial neuropathies (n = 1, 4%), and neoplastic transformation (n = 1, 4%). Of the 23 ears with audiometric data available for review, 65% exhibited sensorineural hearing loss, and 35% mixed hearing loss. Long-term audiometric follow-up was available on two patients, both of whom demonstrated hearing loss at a rate greater than would be expected for normal aging. Two patients underwent successful cochlear implantation, achieving open-set speech recognition. Radiographic features of temporal bone involvement are reviewed and illustrated. Conclusion: This is the largest single-institution clinical series examining patients with PDTB in the English literature. Variable patterns of temporal bone involvement by Paget's disease are observed leading to a diverse set of clinical symptoms, including slowly progressive hearing loss, tinnitus, compressive cranial neuropathies, and benign or malignant tumorigenesis. Involvement typically begins in the petrous apex and progresses laterally. Otic capsule bone demineralization occurs late in the disease process. Cochlear implantation appears to be an effective management strategy for patients with severe-to-profound hearing loss.
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma
McWilliams, Robert R. , Foster, Nathan R. , Mahoney, Michelle R., Smyrk, Thomas C. , Ames, Matthew M. , Horvath, Laura E., Hobday, Timothy J. , Jatoi, Aminah , Meyers, Jeffrey P., Jatoi, Aminah , Murray, Joseph A. , Schneider, Daniel , Goetz, Matthew P. , McWilliams, Robert R

Mayo Clinic

Cancer | May 10, 2017 | Volume: 123 | Issue: 18 | Pages: 3494-3501

10.1002/cncr.30766 | PMID 28493308 Get It

BACKGROUNDOxaliplatin in combination with either 5‐fluorouracil or capecitabine is commonly used as first‐line therapy for patients with small bowel adenocarcinoma. The addition of irinotecan improves survival in other gastrointestinal tumors but at the cost of hematologic toxicity. The authors performed a phase 2 cooperative group study (North Central Cancer Treatment Group N0543, Alliance) using genotype‐dosed capecitabine, irinotecan, and oxaliplatin (gCAPIRINOX), with dosing assigned based on UDP glucuronosyltransferase family 1 member A1 (UGT1A1) genotype to test: 1) whether the addition of irinotecan would improve outcomes; and 2) whether UGT1A1 genotype‐based dosing could optimize tolerability.METHODSPreviously untreated patients with advanced small bowel adenocarcinoma received irinotecan (day 1), oxaliplatin (day 1), and capecitabine (days 2‐15) in a 21‐day cycle and were dosed with gCAPIRINOX according to UGT1A1*28 genotypes (6/6, 6/7, and 7/7).RESULTSA total of 33 patients (17 with the 6/6 genotype, 10 with the 6/7 genotype, and 6 with the 7/7 genotype) were enrolled from October 2007 to November 2013; 73% were male, with a mean age of 64 years (range, 41‐77 years). Location of the primary tumor included the duodenum (58%), jejunum (30%), and ileum (9%). The regimen yielded a confirmed response rate of 37.5% (95% confidence interval, 21%‐56%), with a median progression‐free survival of 8.9 months and a median overall survival of 13.4 months. Neither hematologic toxicity (grade ≥3 in 52.9%, 30.0%, and 33.3%, respectively, of the 6/6, 6/7, and 7/7 genotype groups) nor tumor response rate (41.2%, 33%, and 33%, respectively) were found to differ significantly by UGT1A1 genotype.CONCLUSIONSUGT1A1 genotype‐directed dosing (gCAPIRINOX) appears to be feasible with favorable rates of hematologic toxicity compared with prior 3‐drug studies in unselected patients. Larger studies would be needed to determine the regimen's comparability to oxaliplatin and capecitabine (CapeOx) alone or if response/toxicity differs among patients with different UGT1A1 genotypes. Cancer 2017;123:3494‐501. © 2017 American Cancer Society.